- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Syngene's Q2 revenue rose 2% (H1 +6%), but PAT fell 37% to 67 Cr due to biologics inventory correction and a 20.2 Cr receivables write-off. The company secured a global Phase III trial, is expanding ADC manufacturing capabilities, and maintains full-year guidance.